RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells.

ABSTRACT:

Introduction

Paclitaxel is a widely used drug in the treatment of patients with locally advanced and metastatic breast cancer. However, only a small portion of patients have a complete response to paclitaxel-based chemotherapy, and many patients are resistant. Strategies that increase sensitivity and limit resistance to paclitaxel would be of clinical use, especially for patients with triple-negative breast cancer (TNBC).

Methods

We generated a gene set from overlay of the druggable genome and a collection of genomically deregulated gene transcripts in breast cancer. We used loss-of-function RNA interference (RNAi) to identify gene products in this set that, when targeted, increase paclitaxel sensitivity. Pharmacological agents that targeted the top scoring hits/genes from o

SUBMITTER: Bauer JA 

PROVIDER: S-EPMC2917036 | biostudies-literature | 2010

REPOSITORIES: biostudies-literature